Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

The incidence of consecutive manifestations in Von Hippel-Lindau disease.

van der Horst-Schrivers ANA, Sluiter WJ, Kruizinga RC, van Leeuwaarde RS, Giles R, Olderode-Berends MJW, Links TP.

Fam Cancer. 2019 Jul;18(3):369-376. doi: 10.1007/s10689-019-00131-x.

2.

Muscle Strength and Muscle Mass in Older Patients during Hospitalization: The EMPOWER Study.

Van Ancum JM, Scheerman K, Pierik VD, Numans ST, Verlaan S, Smeenk HE, Slee-Valentijn M, Kruizinga RC, Meskers CGM, Maier AB.

Gerontology. 2017;63(6):507-514. doi: 10.1159/000478777. Epub 2017 Aug 18.

3.

High risk of malnutrition is associated with low muscle mass in older hospitalized patients - a prospective cohort study.

Pierik VD, Meskers CGM, Van Ancum JM, Numans ST, Verlaan S, Scheerman K, Kruizinga RC, Maier AB.

BMC Geriatr. 2017 Jun 5;17(1):118. doi: 10.1186/s12877-017-0505-5.

4.

Change in muscle strength and muscle mass in older hospitalized patients: A systematic review and meta-analysis.

Van Ancum JM, Scheerman K, Jonkman NH, Smeenk HE, Kruizinga RC, Meskers CGM, Maier AB.

Exp Gerontol. 2017 Jun;92:34-41. doi: 10.1016/j.exger.2017.03.006. Epub 2017 Mar 10. Review.

PMID:
28286250
5.

Difference in CXCR4 expression between sporadic and VHL-related hemangioblastoma.

Kruizinga RC, van Marion DM, den Dunnen WF, de Groot JC, Hoving EW, Oosting SF, Timmer-Bosscha H, Derks RP, Cornelissen C, van der Luijt RB, Links TP, de Vries EG, Walenkamp AM.

Fam Cancer. 2016 Oct;15(4):607-16. doi: 10.1007/s10689-016-9879-3.

6.

Calculating optimal surveillance for detection of von Hippel-Lindau-related manifestations.

Kruizinga RC, Sluiter WJ, de Vries EG, Zonnenberg BA, Lips CJ, van der Horst-Schrivers AN, Walenkamp AM, Links TP.

Endocr Relat Cancer. 2013 Dec 20;21(1):63-71. doi: 10.1530/ERC-13-0308. Print 2014 Feb.

PMID:
24132471
7.

Letter to the editor: Pregnancy and von Hippel-Lindau disease.

Frantzen C, van Asselt SJ, Kruizinga RC, Abadie C, Coupier I, Richard S, Alsmeier G, Graff JW, van Pampus MG, Giles RH, Links TP.

J Neurosurg. 2013 Jun;118(6):1380. doi: 10.3171/2012.11.JNS122145. Epub 2013 Apr 12. No abstract available.

PMID:
23581592
8.

CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.

Domanska UM, Timmer-Bosscha H, Nagengast WB, Oude Munnink TH, Kruizinga RC, Ananias HJ, Kliphuis NM, Huls G, De Vries EG, de Jong IJ, Walenkamp AM.

Neoplasia. 2012 Aug;14(8):709-18.

9.

Pregnancy-related hemangioblastoma progression and complications in von Hippel-Lindau disease.

Frantzen C, Kruizinga RC, van Asselt SJ, Zonnenberg BA, Lenders JW, de Herder WW, Walenkamp AM, Giles RH, Hes FJ, Sluiter WJ, van Pampus MG, Links TP.

Neurology. 2012 Aug 21;79(8):793-6. doi: 10.1212/WNL.0b013e3182661f3c. Epub 2012 Aug 8.

PMID:
22875085
10.

A review on CXCR4/CXCL12 axis in oncology: no place to hide.

Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EG, Walenkamp AM.

Eur J Cancer. 2013 Jan;49(1):219-30. doi: 10.1016/j.ejca.2012.05.005. Epub 2012 Jun 9. Review.

PMID:
22683307
11.

Role of chemokines and their receptors in cancer.

Kruizinga RC, Bestebroer J, Berghuis P, de Haas CJ, Links TP, de Vries EG, Walenkamp AM.

Curr Pharm Des. 2009;15(29):3396-416. Review.

PMID:
19860687

Supplemental Content

Loading ...
Support Center